Vaxart (VXRT) said late Monday it has completed enrollment of the 400 participants in the sentinel cohort for its phase 2b trial comparing its oral COVID-19 vaccine candidate with an approved mRNA vaccine.
The cohort includes 200 participants receiving Vaxart's vaccine and 200 receiving the mRNA comparator.
The primary endpoint of the study is the relative efficacy of Vaxart's vaccine candidate compared with the mRNA vaccine for the prevention of symptomatic disease, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments